Trial Profile
Intravitreal aflibercept for the treatment of previously treated exudative age related macular degeneration
Status:
Not yet recruiting
Phase of Trial:
Phase III/IV
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Vascular endothelial growth factor A inhibitors
- Indications Wet macular degeneration
- Focus Therapeutic Use
- Acronyms AAA Study
- Sponsors Bayer
- 17 Oct 2013 New trial record